Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
about
A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.Long-term survival following hepatectomy, radiation, and chemotherapy for recurrent pancreatic carcinoma: a case report.Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients.Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma
P2860
Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
@ast
Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
@en
type
label
Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
@ast
Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
@en
prefLabel
Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
@ast
Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
@en
P2093
P2860
P356
P1476
Multimodality treatment of recurrent pancreatic cancer: Mith or reality?
@en
P2093
Cosimo Sperti
Lucia Moletta
Stefano Merigliano
P2860
P304
P356
10.4251/WJGO.V7.I12.375
P577
2015-12-01T00:00:00Z